B-sejtes prolymphocytás leukaemia (B-PLL) sikeres kezelése FCR-Lite (fludarabin, cyclophosphamid, rituximab) protokoll alkalmazá sával

Translated title of the contribution: Successful treatment of B-cell prolymphocytic leukemia (B-PLL) with FCR-Lite (fl udarabine, cyclophosphamide, rituximab) protocol

Béla Telek, Péter Batár, László Rejto, Miklós Udvardy

Research output: Contribution to journalShort survey

3 Citations (Scopus)


B-cell prolymphocytic leukemia (B-PLL) is a rare disorder characterized by marked lymphocytosis in the peripheral blood, matured lymphocytic infiltration in the bone marrow and splenomegaly. It has a distinct immunophenotype (CD19, CD20, CD22, FMC7, intensive surface immunoglobulin positivity) which helps to differentiate from other lymphoproliferative malignancies. It has a poor prognosis and its treatment is unsettled. The authors present a case of a patient with typical B-PLL treated with FCR-Lite (fludarabine, cyclophosphamide, rituximab) protocol achieving complete hematological (and immunophenotypic) remission. The treatment was well tolerated. Neither major infective complication nor tumor lysis syndrome was observed. According to the author's experience the FCR-Lite protocol can not only be used in patients with CLL but it also can be effective in patients with B-PLL. No clinical experience has been reported yet in the literature with this protocol.

Original languageHungarian
Pages (from-to)1261-1263
Number of pages3
JournalOrvosi hetilap
Issue number31
Publication statusPublished - Aug 1 2010


ASJC Scopus subject areas

  • Medicine(all)

Cite this